- Trials with a EudraCT protocol (30)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
30 result(s) found for: Adrenal hyperplasia.
Displaying page 1 of 2.
EudraCT Number: 2019-004764-22 | Sponsor Protocol Number: SPR001-203 | Start Date*: 2020-10-15 | |||||||||||
Sponsor Name:Spruce Biosciences, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia | |||||||||||||
Medical condition: Classic Congenital Adrenal Hyperplasia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) SE (Trial now transitioned) DE (Ongoing) DK (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) IT (Trial now transitioned) LT (Trial now transitioned) LV (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004381-19 | Sponsor Protocol Number: NBI-74788-CAH2006 | Start Date*: 2021-06-07 | |||||||||||
Sponsor Name:Neurocrine Biosciences, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects with Classic Congenital Adrenal Hyperplasia, Followed by O... | |||||||||||||
Medical condition: Classic Congenital Adrenal Hyperplasia (CAH) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) BE (Ongoing) ES (Ongoing) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004878-34 | Sponsor Protocol Number: ATR-101-202 | Start Date*: 2018-09-18 | |||||||||||
Sponsor Name:Millendo Therapeutics, Inc. | |||||||||||||
Full Title: A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia | |||||||||||||
Medical condition: Classic Congenital Adrenal Hyperplasia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005822-23 | Sponsor Protocol Number: REK231814 | Start Date*: 2012-10-16 | |||||||||||
Sponsor Name:Haukeland University Hospital | |||||||||||||
Full Title: CONTINUOUS SUBCUTANEOUS HYDROCORTISONE INFUSION IN CONGENITAL ADRENAL HYPERPLASIA | |||||||||||||
Medical condition: Congenital adrenal hyperplasia (CAH) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Ongoing) SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004873-17 | Sponsor Protocol Number: NBI-74788-CAH3003 | Start Date*: 2020-10-15 | |||||||||||
Sponsor Name:Neurocrine Biosciences, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-... | |||||||||||||
Medical condition: Classic Congenital Adrenal Hyperplasia (CAH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) CZ (Trial now transitioned) FR (Trial now transitioned) PT (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) AT (Trial now transitioned) NL (Ongoing) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002395-40 | Sponsor Protocol Number: AGO/2013/007 | Start Date*: 2014-03-24 | |||||||||||
Sponsor Name:Ghent University Hospital | |||||||||||||
Full Title: Prospective intervention trial with adjuvant metformin in girls and boys with classic CAH (METFOR CAH). | |||||||||||||
Medical condition: congenital adrenal hyperplasia (CAH) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004765-40 | Sponsor Protocol Number: SPR001-204 | Start Date*: 2020-11-17 | |||||||||||
Sponsor Name:Spruce Biosciences, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Co... | |||||||||||||
Medical condition: Classic Congenital Adrenal Hyperplasia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) SE (Trial now transitioned) PL (Trial now transitioned) LT (Trial now transitioned) LV (Trial now transitioned) IT (Trial now transitioned) EE (Ongoing) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000711-40 | Sponsor Protocol Number: DIUR-005 | Start Date*: 2015-11-19 | |||||||||||
Sponsor Name:Diurnal Ltd | |||||||||||||
Full Title: A Phase III study of efficacy, safety and tolerability of Chronocort® compared with standard glucocorticoid replacement therapy in the treatment of congenital adrenal hyperplasia. | |||||||||||||
Medical condition: Congenital adrenal hyperplasia (CAH); is generally due to 21-hydroxylase deficiency, is a disease of the adrenal cortex characterised by cortisol deficiency with or without aldosterone deficiency, ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) SE (Completed) NL (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005448-32 | Sponsor Protocol Number: DIUR-006 | Start Date*: 2016-07-20 | |||||||||||
Sponsor Name:Diurnal Ltd | |||||||||||||
Full Title: A Phase III extension study of efficacy, safety and tolerability of Chronocort® in the treatment of congenital adrenal hyperplasia (CAH) | |||||||||||||
Medical condition: Congenital adrenal hyperplasia (CAH); is generally due to 21-hydroxylase deficiency, is a disease of the adrenal cortex characterised by cortisol deficiency with or without aldosterone deficiency, ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) DE (Completed) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000051-10 | Sponsor Protocol Number: A091200 | Start Date*: 2008-05-19 |
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge | ||
Full Title: 11C metomidate PET scanning for Conn's syndrome | ||
Medical condition: Primary hyperaldosteronism - Conn's syndrome and bilateral adrenal hyperplasia. Imaging of adrenal lesions using 11C-metomidate PET. Pre-suppression with dexamethasone and/or fludrocortisone to opt... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2015-003996-32 | Sponsor Protocol Number: 69HCL14-0447 | Start Date*: 2015-11-03 | |||||||||||
Sponsor Name:Hospices Civils de Lyon | |||||||||||||
Full Title: Multicentric evaluation of in utero dexamethasone (DEX) on the cognitive development of children at risk of Congenital Adrenal Hyperplasia - PRENATAL DEX Study | |||||||||||||
Medical condition: Patient with Congenital Adrenal Hyperplasia (CAH) or sibling of a CAH patient . Patient no connection with Congenital Adrenal Hyperplasia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000458-40 | Sponsor Protocol Number: Infacort004 | Start Date*: 2015-10-20 |
Sponsor Name:Diurnal Limited | ||
Full Title: Open-label, long-term follow-up of safety and biochemical disease control of Infacort® in neonates, infants and children with congenital adrenal hyperplasia and adrenal insufficiency previously enr... | ||
Medical condition: Adrenal Insufficiency (AI) in children is most commonly due to Congenital Adrenal Hyperplasia (CAH) and results in cortisol deficiency with or without aldosterone deficiency and androgen excess. ... | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-001069-20 | Sponsor Protocol Number: HIDROGUM21 | Start Date*: 2022-01-12 |
Sponsor Name:Vall d'Hebron Hospital Universitari | ||
Full Title: Tolerability and acceptance of two oral hydrocortisone compounding formulation for pediatrics | ||
Medical condition: Adrenal hyperplasia or isolated primary adrenal insufficiency or panhypopituitarism (secondary or tertiary adrenal insufficiency) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004802-24 | Sponsor Protocol Number: NL68556.091.18 | Start Date*: 2019-05-20 |
Sponsor Name:Radboud University Nijmegen Medical Centre | ||
Full Title: Optimizing timing of glucocorticoid treatment in children with congenital adrenal hyperplasia | ||
Medical condition: Congenital adrenal hyperplasia (CAH) is a disorder of adrenal steroid synthesis leading to cortisol deficiency and an increase in androgen production.Treatment in children consists of hydrocortis... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-004956-12 | Sponsor Protocol Number: CORT125134-456 | Start Date*: 2021-02-24 | |||||||||||
Sponsor Name:Corcept Therapeutics Incorporated | |||||||||||||
Full Title: Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients with Cortisol-Secreting Adrenal Adenomas or Hyperplasia (GRADIENT): A Phase 3, Randomized, Double-Blind, Placebo-... | |||||||||||||
Medical condition: Hypercortisolism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Completed) BG (Completed) IT (Completed) RO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004467-26 | Sponsor Protocol Number: DIUR-015 | Start Date*: 2022-02-08 |
Sponsor Name:Diurnal Limited | ||
Full Title: A Phase 3 Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Chronocort in the Treatment of Participants Aged 16 Years and Over with Congenital Adrenal Hyperplasia | ||
Medical condition: Congenital Adrenal Hyperplasia due to 21-hydroxylase deficiency | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-002265-30 | Sponsor Protocol Number: Infacort003 | Start Date*: 2015-02-19 |
Sponsor Name:Diurnal Limited | ||
Full Title: A Phase 3 open-label study of Infacort® in neonates, infants and children less than 6 years of age with adrenal insufficiency. | ||
Medical condition: Adrenal Insufficiency (AI) in children is most commonly due to Congenital Adrenal Hyperplasia (CAH) and results in cortisol deficiency with or without aldosterone deficiency and androgen excess. Cu... | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-000748-32 | Sponsor Protocol Number: SPI-62-CL-2002 | Start Date*: 2023-08-29 | |||||||||||
Sponsor Name:Sparrow Pharmaceuticals, Inc. | |||||||||||||
Full Title: SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor | |||||||||||||
Medical condition: Hypercortisolism Related to a Benign Adrenal Tumor | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001104-37 | Sponsor Protocol Number: ME/2011/3709 | Start Date*: 2014-10-06 | ||||||||||||||||
Sponsor Name:University Hospitals Bristol NHS Foundation Trust | ||||||||||||||||||
Full Title: Pulsed glucocorticoid replacement therapy for patients with adrenocortical insufficiency secondary to Addison’s disease and congenital adrenal hyperplasia | ||||||||||||||||||
Medical condition: Addison's disease and Congenital Adrenal Hyperplasia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003668-29 | Sponsor Protocol Number: DIUR-014 | Start Date*: 2022-02-04 |
Sponsor Name:Diurnal Limited | ||
Full Title: A Randomized, Double-Blind, Active-Controlled, Phase 3 Study of Chronocort Compared with Immediate-Release Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over with Congenital ... | ||
Medical condition: Congenital Adrenal Hyperplasia due to 21-hydroxylase deficiency | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
